Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Advagene Biopharma CoROCO:6709 -2.04%34 EV-to-EBITDA is -15.56 as of Sep. 11, 2026. GuruFocus rates ROCO:6709 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 403 Biotechnology companies, Advagene Biopharma Co ranks worse than 248138.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Advagene Biopharma Co's enterprise value is NT$1,343.67 Mil.
Advagene Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-86.36 Mil. Therefore, Advagene Biopharma Co's EV-to-EBITDA for today is -15.56.
The historical rank and industry rank for Advagene Biopharma Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6709'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.36 Med: 0 Max: 0
Current: -15.56
ROCO:6709's EV-to-EBITDA is ranked worse than 100% of 403
companies
in the Biotechnology industry
Industry Median: 13.21
vs ROCO:6709: -15.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Advagene Biopharma Co (ROCO:6709) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Advagene Biopharma Co's PE Ratio (TTM) for today is calculated as:
Advagene Biopharma Co's share price for today is NT$24.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advagene Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-1.395.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Advagene Biopharma Co EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Advagene Biopharma Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6709 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Advagene Biopharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advagene Biopharma Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Advagene Biopharma Co's EV-to-EBITDA falls into.
Advagene Biopharma Co's current Enterprise Value is NT$1,343.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advagene Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-86.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advagene Biopharma Co (ROCO:6709) has a EV-to-EBITDA of -15.56 as of Sep. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Advagene Biopharma Co. According to the industry distribution chart, Advagene Biopharma Co ranks #999999 out of 403 companies in the Biotechnology industry.
Is Advagene Biopharma Co's EV-to-EBITDA too high?
Advagene Biopharma Co's current EV-to-EBITDA is -15.56. Based on the distribution chart, Advagene Biopharma Co ranks #999999 out of 403 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Advagene Biopharma Co has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Advagene Biopharma Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Advagene Biopharma Co ranks #999999 out of 403 companies for EV-to-EBITDA. This places Advagene Biopharma Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.21, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Advagene Biopharma Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advagene Biopharma Co's current EV-to-EBITDA is -15.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advagene Biopharma Co stock overvalued right now?
Advagene Biopharma Co (ROCO:6709) has a current EV-to-EBITDA of -15.56. The current EV-to-EBITDA is -15.56. Advagene Biopharma Co's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Advagene Biopharma Co (ROCO:6709), the current EV-to-EBITDA is -15.56 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based biotechnology company. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray seasonal flu vaccine, nasal spray COVID-19 vaccine, Immunotherapy for COVID-19, Respiratory Allergy Immunotherapy - Allergic Rhinitis and Asthma ,and other vaccines.
34GF Score
Get the complete analysis for ROCO:6709
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6709 has been successfully added to your 
